<DOC>
	<DOCNO>NCT00388336</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Epoetin alfa administer 60,000 Units every two week cancer patient receive chemotherapy radiation therapy .</brief_summary>
	<brief_title>PROCRIT ( Epoetin Alfa ) 60,000 Units Administered Once Every Two Weeks Anemic Cancer Patients Who Are Not Receiving Chemotherapy Radiation Therapy</brief_title>
	<detailed_description>This open-label ( doctor patient know drug administer ) , non-randomized ( patient assign treatment ) , multi-center pilot study objective investigate effectiveness PROCRIT ( Epoetin alfa ) hematopoietic response ( effect red blood cell ) administer 60,000 Units subcutaneously ( skin ) every two week anemic patient cancer receive chemotherapy radiation therapy . Treatment study drug maximum 12 week follow 4-week observation period last dose study drug administer . Safety efficacy evaluation perform specify interval throughout study include assessment laboratory test ( Complete Blood Count [ CBC ] , Serum Chemistry [ include hemoglobin level ] ) , vital sign ( blood pressure ) , physical examination occurrence severity adverse event . All patient enrol study receive pharmacologic ferrous sulfate 325 mg mouth day equivalent formulation , tolerate , unless determine physician patient receive . All patient 's received injection PROCRIT ( Epoetin alfa ) 60,000 Units skin every two week . If 4 week treatment , patient 's hemoglobin level increase &gt; = 1 g/dL , Epoetin alfa dose increase 80,000 Units every 2 week . Study drug administer maximum 12 week follow 4-week observation period last dose study drug . Epoetin alfa dos reduce hold needed depending patient ' hemoglobin level .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients must histologically confirm diagnosis nonmyeloid malignancy Baseline hemoglobin value &lt; = 11 g/dL unrelated transfusion Patients must receive plan receive chemotherapy radiotherapy within 16week study period . However , patient receive hormonal therapy nonmyelosuppressive therapy allowable Female patient reproductive potential must negative serum pregnancy test screening . Patients must uncontrolled hypertension history ( within 6 month ) uncontrolled cardiac arrhythmia , pulmonary embolus , deep vein thrombosis , ischemic stroke , arterial venous thrombotic event ( exclude superficial thromboses ) , know history chronic coagulation disorder No transfusion within 28 day prior first dose No plan chemotherapy radiation study prior chemotherapy within 8 week radiation within 4 week study entry No prior treatment Epoetin alfa erythropoietic agent within previous two month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Neoplasms , Hemoglobin value</keyword>
	<keyword>PROCRIT</keyword>
	<keyword>Epoetin alfa</keyword>
</DOC>